Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/jci.insight.92865 http://scihub22266oqcxt.onion/10.1172/jci.insight.92865 C5846896!5846896!29046484     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JCI+Insight ä ; 2 (20): ä Nephropedia Template TP {{tp|p=29046484|t=ä. T cells expressing chimeric antigen receptor promote immune tolerance |pdf=|usr=}}{{29046484}} gab.com Text T cells expressing chimeric antigen receptor promote immune tolerance JO: JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=29046484 #FOAvip Cellular therapies based on permanent genetic modification of conventional T cells have emerged as a promising strategy for cancer. However, it remains unknown if modification of T cell subsets, such as Tregs, could be useful in other settings, such as allograft transplantation. Here, we use a modular system based on a chimeric antigen receptor (CAR) that binds covalently modified mAbs to control Treg activation in vivo. Transient expression of this mAb-directed CAR (mAbCAR) in Tregs permitted Treg targeting to specific tissue sites and mitigated allograft responses, such as graft-versus-host disease. mAbCAR Tregs targeted to MHC class I proteins on allografts prolonged islet allograft survival and also prolonged the survival of secondary skin grafts specifically matched to the original islet allograft. Thus, transient genetic modification to produce mAbCAR T cells led to durable immune modulation, suggesting therapeutic targeting strategies for controlling alloreactivity in settings such as organ or tissue transplantation. Twit Text FOAVip T cells expressing chimeric antigen receptor promote immune tolerance ????JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=29046484 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29046484 #FOAvip English Wikipedia <ref>{{Cite pmid|29046484}}</ref> T cells expressing chimeric antigen receptor promote immune tolerance #MMPMID29046484 Pierini A; Iliopoulou BP; Peiris H; Pérez-Cruz M; Baker J; Hsu K; Gu X; Zheng PP; Erkers T; Tang SW; Strober W; Alvarez M; Ring A; Velardi A; Negrin RS; Kim SK; Meyer EH JCI Insight ä[]; 2 (20): ä PMID29046484show ga Cellular therapies based on permanent genetic modification of conventional T cells have emerged as a promising strategy for cancer. However, it remains unknown if modification of T cell subsets, such as Tregs, could be useful in other settings, such as allograft transplantation. Here, we use a modular system based on a chimeric antigen receptor (CAR) that binds covalently modified mAbs to control Treg activation in vivo. Transient expression of this mAb-directed CAR (mAbCAR) in Tregs permitted Treg targeting to specific tissue sites and mitigated allograft responses, such as graft-versus-host disease. mAbCAR Tregs targeted to MHC class I proteins on allografts prolonged islet allograft survival and also prolonged the survival of secondary skin grafts specifically matched to the original islet allograft. Thus, transient genetic modification to produce mAbCAR T cells led to durable immune modulation, suggesting therapeutic targeting strategies for controlling alloreactivity in settings such as organ or tissue transplantation. äT cells expressing chimeric antigen receptor promote immune tolerance (epmc).pdf DeepDyve Pubget Overpricing